Neumora Therapeutics, Inc. NMRA
0.68
(0.02)
(2.86%)
as of 25 Sep
- Market cap
- $135.3M
- P/E
- 0.0×
Follow NMRA
Insider Buys
alert about insiders buying in the last 12 month
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
Current Ratio |
4.50 | 5.09 | 5.87 | 6.85 |
+8 more quarters Free account |
Net Debt/EBITDA |
1.53 | 1.79 | 2.23 | 2.59 | |
Debt/Assets |
42.25% | 34.42% | 28.54% | 11.00% | |
Debt/Equity |
1.19 | 0.75 | 0.53 | 0.15 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.92 | 0.87 | 0.81 | 0.82 | |
Capex/Depreciation |
0.00 | 0.17 | 0.06 | (0.08) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(0.21) | (0.26) | (0.29) | (0.29) | |
Cash per Share |
0.63 | 0.82 | 1.12 | 1.06 | |
Shareholders Equity per Share |
0.24 | 0.39 | 0.64 | 0.82 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.24 | 0.39 | 0.64 | 0.82 | |
Free Cash Flow |
(39.53) | (46.33) | (47.89) | (46.56) | |
Working Capital |
97.10 | 123.32 | 158.09 | 151.24 | |
Capital Expenditures |
0.00 | 0.07 | 0.06 | 0.07 | |
Net Current Asset Value |
44.14 | 70.24 | 103.36 | 131.41 | |
| Other line items | |||||
Quick Ratio |
4.21 | 4.88 | 5.62 | 6.64 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.21) | (0.26) | (0.29) | (0.29) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
2.40 | 3.05 | 3.34 | 3.33 | |
Average Assets |
174.54 | 205.31 | 254.01 | 265.19 | |
Average Common Equity |
113.70 | 149.52 | 195.47 | 226.45 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates